neglected infectious disease

  • 文章类型: Journal Article
    (1)背景:法属圭亚那仅报道了少数关于免疫活性患者组织胞浆菌病的研究。因此,我们对非HIV患者中的组织胞浆菌病住院患者进行了详细的临床描述.(2)方法:这是一个单中心,2008年至2022年在卡宴医院中心进行的回顾性研究.(3)结果:我们的队列由31(91%)成年人(>18岁)和3(9%)儿童组成,性别比例,M:F,1:2。女性的平均年龄高于男性(70岁对54岁)。呼吸道样本的收集占所进行检查的大部分(38%)。56%的患者出现发热(>37°C)。令人惊讶的是,组织胞浆菌病在82%的患者中传播,总病死率为14.7%.然而,在52%(16/31)的成年患者中发现免疫抑制状况,包括淋巴样血液病,糖尿病和免疫抑制药物。结论:本病,虽然罕见,通常被认为是非HIV患者的良性疾病,在我们的队列中呈现相对较高的死亡率。因此,应该怀疑组织胞浆菌病,在高流行地区进行筛查和调查,作为第一道防线,即使在有免疫能力和非HIV患者中,特别是那些有发烧或慢性呼吸道症状的人。
    (1) Background: Only a few studies on histoplasmosis in immunocompetent patients have been reported in French Guiana. Therefore, we conducted a detailed clinical description of hospitalized patients suffering with histoplasmosis among non-HIV patients. (2) Methods: This is a single-center, retrospective study conducted at Cayenne Hospital Center between 2008 and 2022. (3) Results: Our cohort was composed of 31 (91%) adults (>18 years of age) and 3 (9%) children, with a sex ratio, M:F, of 1:2. The median age was higher among the women than among the men (70 versus 54 years). The collection of respiratory samples constituted the majority of the performed examinations (38%). Fever (>37 °C) was found in 56% of patients. Surprisingly, the histoplasmosis was disseminated in 82% of patients with an overall case fatality rate of 14.7%. However, immunosuppressive conditions were found in 52% (16/31) of the adult patients, including lymphoid hemopathies, diabetes and immunosuppressive drugs. Conclusions: This disease, though rare and usually considered a mostly benign disease in non-HIV patients, presented a relatively high mortality rate in our cohort. Thus, histoplasmosis should be suspected, screened and investigated as a first line of defense in highly endemic areas, even in immunocompetent and non-HIV patients, especially those with fever or chronic respiratory symptoms.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Introductory Journal Article
    新兴和新兴传染病(EID)是发病率和死亡率的重要且不断增长的原因,由于全球化和国际贸易,大流行的可能性增加。EID疫苗开发方法仍然面临挑战。本专题探讨了与疫苗开发和测试相关的领域,包括发展中国家面临的独特挑战。针对跨越多个病毒家族的多种病原体的疫苗从过去的活动到未来的商业化进行了探索。讨论了与临床需求相平衡的成本驱动因素,并考虑了罕见疾病带来的独特挑战。
    Emerging and emergent infectious diseases (EIDs) represent a significant and growing cause of morbidity and mortality with increased potential for pandemics due to globalization and international trade. Challenges remain to the approach toward vaccine development for EIDs. This Special Feature explores areas related to vaccine development and testing, including unique challenges posed in the developing world. Vaccines against multiple pathogens spanning a number of viral families are explored with respect to past activities through to future commercialization. Cost drivers balanced against clinical need are discussed and unique challenges posed by rare diseases are considered.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号